Latest News

Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%

Date: April 27, 2021 | READ MORE >

Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19

Date: April 27, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update

Date: April 21, 2021 | READ MORE >

Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects

Date: April 19, 2021 | READ MORE >

Ampio Pharmaceuticals’ Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis

Date: April 6, 2021 | READ MORE >

Ampio Pharmaceuticals to Present at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress

Date: March 29, 2021 | READ MORE >

Ampio Pharmaceuticals to Present at Benzinga Biotech Small Cap Conference

Date: March 19, 2021 | READ MORE >

Ampio Pharmaceuticals Details Early Positive Results for Inhaled Ampion in COVID-19 Respiratory Distress

Date: March 16, 2021 | READ MORE >

Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

Date: March 10, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update

Date: March 3, 2021 | READ MORE >

Ampio Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Date: March 3, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. to Report Annual 2020 Financial Results and Provide Corporate Business Update

Date: February 24, 2021 | READ MORE >

Ampio Brings New Hospitals Online in Trial for Inhalation Treatment of COVID-19 with Ampion

Date: February 23, 2021 | READ MORE >

Ampio Pharmaceuticals, Inc. to Present at Upcoming Investor Conference

Date: February 16, 2021 | READ MORE >

Ampion featured in Denver Business Journal

Date: February 12, 2021 | READ MORE >

Ampio Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in COVID-19 Respiratory Distress

Date: February 1, 2021 | READ MORE >

Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled

Date: January 14, 2021 | READ MORE >

Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients

Date: January 4, 2021 | READ MORE >

AMPIO RECEIVES FEEDBACK FROM THE FDA ON AMPIO’S PROPOSED MODIFICATIONS TO THE SPECIAL PROTOCOL ASSSESSMENT FOR AMPION TREATMENT OF SEVERE OSTEOARTHRITIS OF THE KNEE

Date: December 29, 2020 | READ MORE >

Q&A Regarding Feedback from FDA